Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.

Nicola GianottiAlessandro Cozzi-LepriAndrea AntinoriAntonella CastagnaAndrea De LucaBenedetto Maurizio CelesiaMassimo GalliCristina MussiniCarmela PinnettiVincenzo SpagnuoloAntonella d'Arminio MonforteFrancesca Ceccherini-SilbersteinMassimo Andreoninull null

Published in: PloS one (2017)

Residual viremia and nadir CD4+ counts <100 cells/μL should be regarded as the main factors to be taken into account before considering switching to a PI/r-MT.

Keyphrases

hiv infected
antiretroviral therapy
hiv infected patients
end stage renal disease
newly diagnosed
ejection fraction
induced apoptosis
human immunodeficiency virus
prognostic factors
cell cycle arrest
randomized controlled trial
oxidative stress
cell death
patient reported outcomes
patient reported
study protocol